The impact of methotrexate therapy with vitamin D supplementation on the cardiovascular risk factors among patients with psoriasis; a prospective randomized comparative study.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of psoriasis and psoriatic arthritis in this randomized controlled trial publication.

To assess the value of vitamin D supplementation on clinical response as well as changes in cardiovascular risk parameters in psoriasis patients treated with methotrexate.

Who Took Part

According to the abstract, 30 patients were involved.

Lipid profile, HsCRP, carotid intima-media thickness (CIMT) and blood pressure (BP) measurements were recorded before and after the therapy.

How the Study Was Run

In design terms this was a randomized study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

What Was Measured

The subject headings attached to it are C-Reactive Protein, Cardiovascular Diseases, Carotid Intima-Media Thickness, Cholesterol, Dietary Supplements, Heart Disease Risk Factors and Lipids.

The authors tagged it with the keywords Cardiovascular risk, methotrexate, psoriasis and vitamin D.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 30 patients in people with psoriasis and psoriatic arthritis.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (The Journal of dermatological treatment), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Psoriasis and psoriatic arthritis research.